Skip to main content

Table 2 Baseline clinical and demographic patient characteristics

From: Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

 Patients with CRSwNP (n = 17)Patients without CRSwNP (n = 106)p value
Age (years)51.6 ± 12.552.9 ± 13.70.626
Female (%)58.862.30.786
BMI (kg/m2)24.8 ± 4.126.4 ± 4.80.155
Time from asthma diagnosis (years)12.9 ± 9.918.6 ± 14.00.161
FEV1 (l)1.74 ± 0.801.70 ± 0.720.735
FEV1 % predicted, median (Q1–Q3)61.01 (48.53–70.58)54.18 (45.65–69.23)0.690
ACQ2.87 ± 1.602.98 ± 1.020.706
No. of asthma exacerbations in the previous 12 months5.13 ± 4.134.54 ± 4.080.413
Monthly dose of omalizumab, mg553.13 ± 303.57521.23 ± 331.680.5233
  1. Data are mean ± SD unless otherwise stated
  2. ACQ Asthma Control Questionnaire, BMI body mass index, FEV1 forced expiratory volume in 1 s, CRSwNP chronic rhinosinusitis with nasal polyps, SD standard deviation